Watch Out, Pfizer: This $2 Billion Biotech Is Coming for You

Pfizer (NYSE: PFE) is out to an early lead with Vyndaqel, a drug that treats cardiomyopathy caused by transthyretin (TTR)-mediated amyloidosis (ATTR-CM), in which the TTR protein aggregates in the heart and ultimately interferes with its function. During the third quarter, the drug's first full quarter on the market in the U.S., Pfizer logged $79 million in sales of Vyndaqel.